Previous 10 | Next 10 |
home / stock / wllw:cc / wllw:cc news
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT Canada NewsWire SUNNYVALE, Calif. , Jan. 31, 2024 /CNW/ - Willow Biosciences Inc. ...
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS Canada NewsWire SUNNYVALE, Calif. , Jan. 16, 2024 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnol...
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023 Canada NewsWire Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company Anticipate closing at least three new partnership development agreements including one...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share a significant development. The company has unveiled a noteworthy partnership with a Nasdaq-listed biopharmaceutical company, with a shared objective of forging precise and efficient manufact...
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS Canada NewsWire Program brings immediate R&D revenue and first commercial supply revenue as early as 2024 ...
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Canada NewsWire Record revenues for the third quarter and the nine months ended September 30, 2023 Patent application filed for a process to produce corticosteroids at an ...
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING Canada NewsWire CALGARY, AB , Oct. 10, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF)...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a significant collaboration agreement between Willow Biosciences and Suanfarma. The partnership is focused on optimizing cell line productivity for manufacturing a high-volume anti-in...
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION Canada NewsWire SUNNYVALE, Calif. , Oct. 3, 2023 /CNW/ - Willow Biosciences Inc., ( "Willow" ) (TSX: WLLW) (OTCQB: CANSF) and SUANFARM...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive appl...
News, Short Squeeze, Breakout and More Instantly...
Willow Biosciences Inc. Company Name:
WLLW:CC Stock Symbol:
TSXC Market:
Willow Biosciences Inc. Website:
WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ CALGARY, AB , July 18, 2024 /CNW/ - Willow Biosciences Inc. ...
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM Canada NewsWire Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates ...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share the company's plans to raise approximately $3 million. This capital will be used to support Willow Bioscience's recent partnership announcement with Laurus Labs. Dr. Savile explained tha...